Canada markets closed

Adaptimmune Therapeutics plc (ADAP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.0750+0.0150 (+1.42%)
At close: 04:00PM EDT
1.0900 +0.01 (+1.40%)
After hours: 07:36PM EDT
Currency in USD

Valuation Measures4

Market Cap (intraday) 274.73M
Enterprise Value 153.03M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)3.59
Price/Book (mrq)6.95
Enterprise Value/Revenue 2.54
Enterprise Value/EBITDA -1.19

Trading Information

Stock Price History

Beta (5Y Monthly) 2.38
52-Week Change 3-24.83%
S&P500 52-Week Change 322.36%
52 Week High 32.0500
52 Week Low 30.4200
50-Day Moving Average 31.3745
200-Day Moving Average 30.8963

Share Statistics

Avg Vol (3 month) 32.04M
Avg Vol (10 day) 31.29M
Shares Outstanding 5255.56M
Implied Shares Outstanding 6226.17M
Float 8987.1M
% Held by Insiders 10.39%
% Held by Institutions 167.52%
Shares Short (Apr 15, 2024) 43.41M
Short Ratio (Apr 15, 2024) 42.55
Short % of Float (Apr 15, 2024) 42.00%
Short % of Shares Outstanding (Apr 15, 2024) 41.33%
Shares Short (prior month Mar 15, 2024) 43.11M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Mar 30, 2018
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin -188.90%
Operating Margin (ttm)-21,582.68%

Management Effectiveness

Return on Assets (ttm)-28.22%
Return on Equity (ttm)-187.61%

Income Statement

Revenue (ttm)60.28M
Revenue Per Share (ttm)0.30
Quarterly Revenue Growth (yoy)-97.90%
Gross Profit (ttm)N/A
EBITDA -128.2M
Net Income Avi to Common (ttm)-113.87M
Diluted EPS (ttm)-0.5400
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)146.94M
Total Cash Per Share (mrq)0.1
Total Debt (mrq)25.23M
Total Debt/Equity (mrq)63.87%
Current Ratio (mrq)2.85
Book Value Per Share (mrq)0.17

Cash Flow Statement

Operating Cash Flow (ttm)-140.88M
Levered Free Cash Flow (ttm)-73.76M